The forecasted data from 2024 to 2028 indicates a steady increase in the import of antisera and other blood fractions to France, beginning at 6.0282 million kilograms in 2024 and reaching 6.6619 million kilograms in 2028. In 2023, actual import volumes stood at 5.874 million kilograms. Year-on-year growth shows a consistent uptick, with each year witnessing a modest rise. The average compound annual growth rate (CAGR) over the five-year period from 2024 to 2028 is expected to reflect a stable and robust demand increase for these medical imports.
Future trends to watch for include potential impacts from technological advancements in blood fractionation, regulatory changes in the EU pharmaceutical sector, and shifts in healthcare demand dynamics driven by demographic changes. Monitoring geopolitical factors that may affect trade agreements and the overall stability of the supply chain will also be crucial.
